

5 reasons to choose Devyser Thalassemia

Detection of novel variants

In a study from Turkey, Devyser Thalassemia uncovered **13 new and rare mutations**, expanding knowledge of the genetic landscape of thalassemia¹.



Cost & time-effective

With just **45 minutes hands-on time** Devyser Thalassemia provides an efficient and simplified testing solution. NGS thalassemia testing has shown cost-benefits compared to standard methods⁴.

User-friendly software



Amplicon Suite provides reliable variant detection, with **unique direct detection of CNVs** and easy analysis.

Upgraded thalassemia testing

NGS methods offer precise results, reducing the likelihood of false negatives and positives and **enhancing diagnostic accuracy** compared to traditional methods^{2,3}.

Rapid results
Devyser Thalassemia provides results in **5 hours**. The Cyprus Institute of Neurology and Genetics (CING) reduced their end-to-end thalassemia testing from 13 days to 3-4 days.

Learn more:



1. Ozalp O, Anlas O. Detection of 13 Novel Variants and Investigation of Mutation Distribution by Next Generation Sequencing in Hemoglobinopathies: A Single Center Experience. Indian J Hematol Blood Transfus. 2024 Apr;40(2):268-280. doi: 10.1007/s12288-023-01694-7. Epub 2023 Oct 3. PMID: 38708170; PMCID: PMC11065806.

2. Aliyeva, G., Asadov, C., Mammadova, T., Gafarova, S. & Abdulalimov, E. (2019). Thalassemia in the laboratory: pearls, pitfalls, and promises. Clinical Chemistry and Laboratory Medicine (CCLM), 57(2), 165-174. <https://doi.org/10.1515/cclm-2018-0647>

3. Zhao, J., Li, J., Lai, Q., & Yu, Y. (2020). Combined use of gap-PCR and next-generation sequencing improves thalassaemia carrier screening among premarital adults in China. Journal of clinical pathology, 73(8), 488-492. <https://doi.org/10.1136/jclinpath-2019-206339>

4. Suhaimi, S. A., Zulkifli, I. N., Ghani, H., & Abdul-Hamid, M. R. W. (2022). Applications of next generation sequencing in the screening and diagnosis of thalassemia: A mini-review. Frontiers in pediatrics, 10, 1015769. <https://doi.org/10.3389/fped.2022.1015769>

Dvysr®

Devyser – a new level of certainty

Devyser Thalassemia is CE-IVD marked but not FDA-cleared. Availability in each country depends on local regulatory marketing authorization status. Please consult your local sales representative for details.

Distributed by Abacus dx

1800 ABACUS (AUS) 0800 222 170 (NZ) | info@abacusdx.com | www.abacusdx.com

abacus dx